Literature DB >> 222676

Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs.

A H From, J S Fong, R A Good.   

Abstract

The effects of endotoxin (lipopolysaccharide [LPS]) on the pathogenesis of canine endotoxin shock were compared with those of LPS which had interacted with polymyxin B sulfate prior to administration. Both LPS and polymyxin B-modified LPS caused comparable early decreases in aortic blood pressure, leukocyte and platelet numbers, and serum complement levels. However, in dogs receiving polymyxin B-modified LPS the late hypotensive phase was significantly ameliorated and lethality was significantly decreased. These data indicate that polymyxin B-modified LPS, though significantly less lethal than unmodified LPS, was capable of major interactions with several components of the humoral defense system, and support the concept that such interactions are not determinative in the pathogenesis of canine endotoxin shock.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 222676      PMCID: PMC414215          DOI: 10.1128/iai.23.3.660-664.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Neutralization of the hemodynamic effects of endotoxin by polymyxin B.

Authors:  J D Palmer; D Rifkind
Journal:  Surg Gynecol Obstet       Date:  1974-05

2.  Modification of human neutrophil response to endotoxin with polymyxin B sulfate.

Authors:  J J Corrigan; O E Sieber; H Ratajczak; B B Bennett
Journal:  J Infect Dis       Date:  1974-10       Impact factor: 5.226

3.  Endotoxin-induced intravascular coagulation: prevention with polymyxin B sulfate.

Authors:  J J Corrigan; B M Bell
Journal:  J Lab Clin Med       Date:  1971-05

4.  Prevention by polymyxin B of endotoxin lethality in mice.

Authors:  D Rifkind
Journal:  J Bacteriol       Date:  1967-04       Impact factor: 3.490

5.  Action of polymyxin B on bacterial membranes. 1. Binding to the O-antigenic lipopolysaccharide of Salmonella typhimurium.

Authors:  J Bader; M Teuber
Journal:  Z Naturforsch C       Date:  1973 Jul-Aug       Impact factor: 1.649

6.  Significane of intravascular coagulation in canine endotoxin shock.

Authors:  A H From; W W Spink; D Knight; H Gewurz
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

7.  Inhibition of the biologic effects of endotoxin on neutrophils by polymyxin B sulfate.

Authors:  R M Bannatyne; N M Harnett; K Y Lee; W D Biggar
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

8.  Neutralization of endotoxin toxicity in chick embryos by antibiotics.

Authors:  D Rifkind; J D Palmer
Journal:  J Bacteriol       Date:  1966-10       Impact factor: 3.490

9.  Role of platelets in the pathogenesis of canine endotoxin shock.

Authors:  A H From; J S Fong; T Chiu; R A Good
Journal:  Infect Immun       Date:  1976-06       Impact factor: 3.441

10.  Prevention of the generalized Shwartzman reaction and endotoxin lethality by polymyxin B localized in tissues.

Authors:  W A Craig; J H Turner; C M Kunin
Journal:  Infect Immun       Date:  1974-08       Impact factor: 3.441

View more
  11 in total

1.  Lactulose inhibits endotoxin induced tumour necrosis factor production by monocytes. An in vitro study.

Authors:  J W Greve; D J Gouma; P A von Leeuwen; W A Buurman
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

Review 2.  Clinical relevance of antibiotic-induced endotoxin release.

Authors:  J M Prins; S J van Deventer; E J Kuijper; P Speelman
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

3.  Polymyxin B sulphate protects cats against the haemodynamic and metabolic effects of E. coli endotoxin.

Authors:  B Hughes; B R Madan; J R Parratt
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

4.  Polymyxin B inactivation of lipopolysaccharide in vaccines of Gram-negative bacteria.

Authors:  M Cooperstock; L Riegle
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

5.  In vitro inhibition of lipopolysaccharide-induced bone resorption by polymyxin B.

Authors:  W Harvey; M Wilson; S Meghji
Journal:  Br J Exp Pathol       Date:  1986-10

6.  Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide.

Authors:  R L Danner; K A Joiner; M Rubin; W H Patterson; N Johnson; K M Ayers; J E Parrillo
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  Enteric coated polymyxin B in the treatment of hyperammonemia and endotoxemia in liver cirrhosis.

Authors:  Y Adachi; M Enomoto; M Adachi; M Suwa; Y Nagamine; T Nanno; T Hashimoto; H Inoue; T Yamamoto
Journal:  Gastroenterol Jpn       Date:  1982-12

8.  Lipid A dependence of the ocular response to circulating endotoxin in rabbits.

Authors:  E L Howes; D C Morrison
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

9.  PMX-622 (polymyxin B-dextran 70) does not alter in vitro activities of 11 antimicrobial agents.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia.

Authors:  S E Bucklin; P Lake; L Lögdberg; D C Morrison
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.